International clinical trial yields mixed results with unclear cognitive effects but promising biomarker results
Tuberculosis (TB) is a deadly infection that occurs in every part of the world. The standard treatment for TB, a six-month multidrug regimen, has not changed in more than 40 years. Patients can find it difficult to complete the lengthy regimen, making it more likely that treatment resistance will develop.
An international team of researchers, led by UC Davis Health, has developed a new therapeutic approach to treating psoriatic arthritis, a chronic inflammatory disease affecting the joints. Using a novel chemical blocker targeting chemokine proteins, the researchers were able to significantly reduce skin and joint inflammation in a mouse model with psoriasis and psoriatic arthritis.
St. Jude Children’s Research Hospital provides the first gene therapy manufacturing and distribution cost report for hemophilia B.
Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus (HBV), the most common cause of liver cancer in the world.